The innovative biopharma industry is ready to lobby the new Congress and incoming Trump Administration for enactment of drug user fee legislation in 2017 in a way that does not disturb the carefully negotiated agreement with FDA.
The potential for lawmakers or the new administration to seek changes in the commitments negotiated for the sixth iteration of...







